FDA Inspection 1243454 — Agno Pharma Jiangsu

Agno Pharma Jiangsu — FEI 3009530424

The FDA completed an inspection of Agno Pharma Jiangsu on Jun 7, 2024 in Lianyungang. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI)
End Date
Jun 7, 2024
Fiscal Year
2024
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Lianyungang (China)

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.